A Phase II, Randomized, Double Blind, Placebo-controlled, Parallel Design, Dose Ranging, Multi-center Trial of Four Levels of Exposure of QGE031 s.c. for 16 Weeks in Subjects Aged 18-50 Years of Age With Peanut Allergy.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2013
At a glance
- Drugs Ligelizumab (Primary)
- Indications Peanut hypersensitivity
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 07 Sep 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by European Clinical Trials Database.
- 25 Mar 2012 New trial record
- 23 Mar 2012 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database record.